Thus, our finding that Bmi-1 upregulates VEGF-C expression in glioma cells through NF-κB activation further underscores the importance of VEGF-C in glioma angiogenesis and provides a basis for using VEGF-C as a surveillance biomarker during anti-Bmi-1 therapy. This evidence concerns the gene VEGFC and central nervous system cancer.